Ubs Asset Management Americas Inc Denali Therapeutics Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 6,766,916 shares of DNLI stock, worth $95.8 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
6,766,916
Previous 3,582,874
88.87%
Holding current value
$95.8 Million
Previous $73 Million
26.04%
% of portfolio
0.02%
Previous 0.02%
Shares
26 transactions
Others Institutions Holding DNLI
# of Institutions
234Shares Held
124MCall Options Held
37.3KPut Options Held
7.9K-
Black Rock Inc. New York, NY13.2MShares$187 Million0.01% of portfolio
-
Baillie Gifford & CO12.1MShares$171 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$167 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA11.4MShares$162 Million0.03% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U05.36MShares$75.8 Million0.37% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $1.9B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...